Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Goldman
John M
JM
Department of Haematology, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom. jgoldman@imperial.ac.uk
Melo
Junia V
JV
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D015398:Signal Transduction; D033581:Stem Cell Transplantation; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl